Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
Conditions: Malignant Pleural Mesothelioma Interventions: Drug: Lenvatinib; Drug: Pemetrexed; Drug: Cisplatin/Carboplatin; Drug: Pembrolizumab Sponsors: Hyogo Medical University; Merck Sharp& Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Asbestosis | Cancer & Oncology | Chemotherapy | Merck | Mesothelioma | Research | Study